Pure Global
NCT06341296

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer
West China Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Irinotecan Liposome
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
West China Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Dec 01, 2026
Enrollment
86 participants
Primary outcome

Objective response rate

Summary

To evaluate the objective response rate, disease control rate, progression-free survival,
 overall survival, surgical conversion rate and safety of irinotecan liposome combined with
 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer
 patients.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06341296
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06341296 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 86 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.